Deutsche Bank AG Decreases Position in Prothena Co. PLC (NASDAQ:PRTA)

Deutsche Bank AG decreased its stake in Prothena Co. PLC (NASDAQ:PRTA) by 5.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,191 shares of the biotechnology company’s stock after selling 4,793 shares during the period. Deutsche Bank AG owned approximately 0.20% of Prothena worth $837,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PRTA. Bank of Montreal Can boosted its position in shares of Prothena by 85.2% in the fourth quarter. Bank of Montreal Can now owns 6,555 shares of the biotechnology company’s stock worth $103,000 after buying an additional 3,015 shares during the period. Virginia Retirement Systems ET AL acquired a new position in shares of Prothena in the first quarter worth about $110,000. Public Employees Retirement Association of Colorado lifted its stake in shares of Prothena by 58.9% in the first quarter. Public Employees Retirement Association of Colorado now owns 10,984 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 4,071 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Prothena by 81.0% in the first quarter. SG Americas Securities LLC now owns 16,533 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 7,399 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in shares of Prothena by 134.6% in the first quarter. BNP Paribas Arbitrage SA now owns 17,178 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 9,855 shares in the last quarter. 93.05% of the stock is owned by institutional investors.

Shares of Prothena stock opened at $10.46 on Wednesday. The company has a current ratio of 21.05, a quick ratio of 21.05 and a debt-to-equity ratio of 0.06. The business’s 50 day simple moving average is $10.78 and its 200-day simple moving average is $11.97. The stock has a market capitalization of $403.90 million, a price-to-earnings ratio of -5.18 and a beta of 1.75. Prothena Co. PLC has a twelve month low of $6.71 and a twelve month high of $17.63.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.23 million. Prothena had a negative return on equity of 28.71% and a negative net margin of 10,452.67%. Sell-side analysts predict that Prothena Co. PLC will post -2.43 earnings per share for the current year.

Several research analysts recently commented on the company. BidaskClub cut Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, June 9th. Zacks Investment Research upgraded Prothena from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Saturday, June 6th. ValuEngine cut Prothena from a “hold” rating to a “sell” rating in a research note on Wednesday, April 1st. Oppenheimer restated a “hold” rating on shares of Prothena in a research note on Wednesday, May 13th. Finally, Nomura restated a “buy” rating and set a $19.00 price objective on shares of Prothena in a research note on Sunday, May 10th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $15.75.

Prothena Company Profile

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Featured Story: Management Fee

Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.